Ideaya Biosciences Inc Earnings
The next earnings date for Ideaya Biosciences Inc is August 4, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of Ideaya Biosciences Inc Earnings
| 08/04/2026 | $-1.18 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Ideaya Biosciences Inc Earnings: Historical
| 05/05/2026 | Before Market | $-1.11 | -13.27% |
| 02/17/2026 | Before Market | $-0.94 | 1.05% |
| 11/04/2025 | Before Market | $1.33 | 341.82% |
| 08/05/2025 | Before Market | $-0.88 | -11.39% |
| 05/06/2025 | Before Market | $-0.82 | -18.84% |
| 02/18/2025 | Before Market | $-1.49 | -139.36% |
| 11/05/2024 | Before Market | $-0.60 | 4.76% |
| 08/06/2024 | Before Market | $-0.68 | -28.30% |
| 05/07/2024 | Before Market | $-0.53 | -6.00% |
| 02/20/2024 | Before Market | $-0.52 | -13.04% |
More About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R
“Ideaya Biosciences Inc Earnings” Can Refer to the Ideaya Biosciences Inc Earnings Date
Some people say “Ideaya Biosciences Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Ideaya Biosciences Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Ideaya Biosciences Inc Stock on the Earnings Date
If you own Ideaya Biosciences Inc stock (IDYA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Ideaya Biosciences Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Ideaya Biosciences Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Ideaya Biosciences Inc Earnings
You can contact us any time if you would like to ask questions about Ideaya Biosciences Inc earnings or anything else related to the stock market.